Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease

NCT00471211 is registered in ClinicalTrials.gov with Prana Biotechnology Limited as lead sponsor.

NCT NCT00471211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00471211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease
Lead sponsor
Prana Biotechnology Limited
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
December 31, 2007
Enrollment
80 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease